Biotech Values

[DewDiligence]

FCSC—not much changed, still selling shares to keep it going.

Well, the old FCSC would certainly not have been able to sell shares at the market price with no warrants. The degree to which today’s attractive financing terms were due to the bull market for biotech in general vs the company’s actual prospects is hard to say, but I’m willing to reconsider my view of a company if the circumstances change.